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Abstract
Background: Single nucleotide polymorphisms (SNPs) from GCK, GCKR, G6PC2 and MTNR1B were found to modulate the
fasting glucose levels. The current study aimed to replicate this association in the Chinese population and further analyze
their effects on biphasic insulin secretion.
Methods/Principal Findings: SNPs from GCK, GCKR, G6PC2 and MTNR1B were genotyped in the Shanghai Chinese, including
3,410 type 2 diabetes patients and 3,412 controls. The controls were extensively phenotyped for the traits related to glucose
metabolism and insulin secretion. We replicated the association between GCK rs1799884, G6PC2 rs16856187 and MTNR1B
rs10830963 and fasting glucose in our samples (p=0.0003,2.0610
28). GCK rs1799884 and G6PC2 rs16856187 showed
association to HOMA-b, insulinogenic index and both first- and second-phases insulin secretion (p=0.0030,0.0396).
MTNR1B rs10830963 was associated to HOMA-b, insulinogenic index and first-phase insulin secretion (p=0.0102,0.0426),
but not second-phase insulin secretion (p=0.9933). Combined effect analyses showed individuals carrying more risk allele
for high fasting glucose tended to have a higher glucose levels at both fasting and 2 h during OGTTs (p=1.7610
213 and
0.0009, respectively), as well as lower HOMA-b, insulinogenic index and both first- and second-phases insulin secretion
(p=0.0321,1.1610
27).
Conclusions/Significance: We showed that SNPs from GCK, G6PC2 and MTNR1B modulated the fasting glucose levels in the
normoglycaemic population while SNPs from G6PC2 and GCKR was associated with type 2 diabetes. Moreover, we found
GCK and G6PC2 genetic variants were associated to both first- and second-phases insulin secretion while MTNR1B genetic
variant was associated with first-phase insulin secretion, but not second-phase insulin secretion.
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Introduction
Fasting glucose plays a central role in the pathogenesis of
diabetes and its complications [1,2]. Studies in twins and families
had shown that genetic factors contributed to fasting glucose levels
in the population [3,4]. However, the genes regulating fasting
glucose levels are different from the genes affecting either type 1 or
type 2 diabetes susceptibility, although fasting glucose is an
important component of diabetes diagnosis. Recently, advance
was made in identifying genes regulating fasting glucose through
genome-wide association studies. The first wave of discovery of
fasting glucose genes identified glucokinase (GCK), glucokinase
regulatory protein (GCKR), glucose-6-phosphatase catalytic subunit
2( G6PC2) and melatonin receptor 1B (MTNR1B) [5,6,7]. More
recently, the meta-analysis identified additionally 9 new loci
implicated in fasting glucose homeostasis, including ADCY5,
MADD, ADRA2A, CRY2, FADS1, GLIS3, SLC2A2, PROX1 and
C2CD4B) [8]. Although these genes were identified originally from
the European descent populations, replication studies in the
Chinese populations confirmed some of their effects on the traits
related to glucose metabolism. Two studies, focused on GCK and
GCKR, were performed in other Chinese populations. They found
GCK rs1799884 was associated with high fasting glucose while
GCKR rs780094 was associated with high triglyceride level
and type 2 diabetes [9,10]. Another study replicated the effects
of MTNR1B rs10830963 on fasting glucose and type 2 diabetes
[11]. We previously also studied G6PC2 using a tagging single
nucleotide polymorphism (SNP) approach covering all the
common variants spanning the gene. We identified the SNP
rs16856187 was associated to the fasting glucose levels as well as
type 2 diabetes risks in the Chinese [12]. These genes were linked
to beta cell function in various populations mainly because of their
association to HOMA-b. However, HOMA-b cannot be used to
quantify the biphasic insulin response after stimulated by food.
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11761Thus the effects of these genes on first- and second-phases of
insulin secretion remained largely unknown. To investigate the
effects of GCK, GCKR, G6PC2 and MTNR1B variants on biphasic
insulin secretion, we tested the individual as well as combined
effects of these variants on the traits related to glucose metabolism,
especially multiple measurements on insulin secretion.
Methods
Ethics statement
This study was approved by the institutional review board of
Shanghai Jiao Tong University Affiliated Sixth People’s Hospital
in accordance with the principle of the Helsinki Declaration II.
Written informed consent was obtained from each participant.
Participants
We recruited a total of 6,822 participants of Chinese Han
ancestry residing in Shanghai, comprising 3,410 type 2 diabetes
patients and 3,412 controls. The inclusion criteria were described
previously [13]. Briefly, all cases were unrelated type 2 diabetes
patients defined according to 1999 WHO criteria and were treated
with oral hypoglycemic agents and/or insulin [14]. The controls
were selected from community-based random sample epidemio-
logical studies of diabetes and related metabolic disorders. All
controls were unrelated subjects with normal glucose tolerance as
assessed by a standard 75 g oral glucose tolerant tests (OGTTs),
and negative family history of diabetes. Among them, 1,892 cases
and 1,808 controls overlapped with previous studies [12,13]. The
clinical characteristics were shown in Table 1.
For a SNP with minor allele frequency over 0.2, our case-
control samples had over 80% power to detect the minimum OR
of 1.13 and our control samples had over 90% power to detect the
minimum effect size of 0.05 mmol/l per allele on fasting glucose at
a level of significance of 0.05.
Clinical measurements
Phenotypes for anthropometric and biochemical traits related to
glucose metabolism were extensively measured for both case and
control subjects. OGTTs were performed in the controls in the
morning after an overnight fast. Blood samples were obtained at
the fasting and 2 h during OGTTs. Plasma glucose and serum
insulin were measured. Basal insulin sensitivity and beta cell
function were calculated from fasting plasma glucose and insulin
using HOMA [15]. First- and second-phase insulin secretions were
estimated using the glucose and insulin levels at 0 and 120 min
during the OGTT and BMI measurements [16]. In a subgroup of
controls, plasma glucose and serum insulin levels at 30 min during
OGTTs were also measured. The insulinogenic index was
calculated as the ratio of the increment in insulin concentration
to the increment in glucose concentration ([30 min insulin –
fasting insulin]/[30 min glucose – fasting glucose]).
SNP selection, genotyping and quality control analysis
We selected four previously reported SNPs from loci affecting
fasting glucose, including GCK rs1799884, GCKR rs780094, G6PC2
rs16856187 and MTNR1B rs10830963 [5,6,7,9,10,11,12]. The
SNPs were genotyped using primer extension of multiplex
products with detection by matrix-assisted laser desorption
ionization–time of flight mass spectroscopy using a MassARRAY
Compact Analyzer (Sequenom, San Diego, CA, USA). Detailed
information on genotype data quality controls was mentioned
previously [13]. After all the quality control checks, 6,540
individuals (3,228 cases and 3,312 controls) and all four SNPs
were analyzed.
Statistical analysis
The Hardy-Weinberg equilibrium test was performed in the
cases and controls separately before association analysis. The
allelic frequencies between the diabetic patients and controls were
compared using x
2 tests, and ORs with 95% CIs were presented.
Quantitative traits were analyzed by linear regression adjusted for
age, gender and BMI, and the regression coefficients (bs) were
presented. An additive genetic model was used for the analysis,
unless specified otherwise. All skewly distributed quantitative traits
were logarithmically transformed to approximate univariate
normality. Permutations (100,000 times for fasting glucose and
10,000 times for other traits) were performed for each trait to
assess empirical p values using PLINK [17] in order to adjust the
multiple comparison. The statistical analyses were performed
using SAS for Windows (version 8.0; SAS Institute, Cary, NC,
USA) unless specified otherwise. A two-tailed p value of ,0.05 was
considered statistically significant.
Results
All SNPs were in Hardy-Weinberg equilibrium. We analyzed the
effects of these loci on glucose levels in the controls. GCK rs1799884,
G6PC2 rs16856187 and MTNR1B rs10830963 showed associations
to fasting glucose (p=7.2 610
25, 0.0003 and 2.0610
28;e m p i r i c a l
p=0.00015, 0.00099 and 0.00001) (Table 2). After further adjusting
for age, gender and BMI as confounders, the effects of these SNPs
were similar to the previous reports in European and Asian
populations (b=0.04820.06 mmol/L). No interaction effect was
detected between GCK, GCKR and G6PC2 SNPs (data not shown).
GCK rs1799884 and G6PC2 rs16856187 showed effects on the 2 h
glucose levels during the OGTTs (GCK: b=0.1160.04 per A allele,
p=0.0089, empirical p=0.0255; G6PC2: b=0.0760.03 per C allele,
p=0.0153, empirical p=0.0517). For the lipid profiles, GCKR
rs780094 and G6PC2 rs16856187 were associated with triglyceride
(p=0.0002 and 0.0118, respectively).
To further investigate the impact of these variants on beta cell
function, we analyzed their effects on HOMA-b, estimated first-
and second-phases of insulin secretion in the controls with both
fasting and 2 h insulin data available (n=2,376), as well as the
insulinogenic index in the controls with fasting, OGTT 30 min
glucose and insulin data available (n=960). As shown in Table 2,
GCK rs1799884 was associated with HOMA-b, insulinogenic
index and both first- and second phases of insulin secretion
(p=0.0396, 0.0129, 0.0030 and 0.0223, respectively). G6PC2
rs16856187 showed evidence for association to first-phase insulin
secretion (p=0.0108), and second-phase insulin secretion under a
dominant genetic model (p=0.0431). MTNR1B rs10830963 was
associated with HOMA-b, insulinogenic index and first-phase
insulin secretion (p=0.0426, 0.0162 and 0.0102, respectively), but
not second-phase insulin secretion (p=0.9933). GCKR rs780094
showed no association to the traits related to insulin secretion.
Table 1. Clinical characteristics of the study samples.
Cases Controls
Samples (n) 3,410 3,412
Male/female (n) 1,871/1,589 1,364/2,048
Age (years) 60.33612.49 50.10614.27
BMI (kg/m
2) 24.3863.51 23.4663.25
Data are shown as mean6SD or n.
doi:10.1371/journal.pone.0011761.t001
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risk for type 2 diabetes susceptibility. As shown in Table 3, we
found GCKR rs780094 and G6PC2 rs16856187 showed evidence
for association to type 2 diabetes (p=5.25610
25 and 0.0021,
respectively). No association was detected between GCK rs1799884
and MTNR1B rs10830963.
The combined effects of the SNPs from GCK, G6PC2 and
MTNR1B were then examined in our samples. We only included
the samples without genotype missing (n=3,212). We found the
individuals carrying more risk alleles tended to have a higher
glucose levels at both fasting and 2 h during OGTT (fasting
glucose: b=0.04mmol/l per allele, p=1.69610
213; 2 h glucose:
b=0.05mmol/l per allele, p=0.0009), and lower HOMA-b
(p=0.0011), insulinogenic index (p=0.0017) and both first- and
second-phases of insulin secretion (p=1.11610
27 and 0.0321,
respectively) (Figure 1).
Discussion
In this study, we analyzed the effects of GCK, GCKR, G6PC2 and
MTNR1B SNPs on the traits related to glucose metabolism. We
replicated previous findings that GCK, G6PC2 and MTNR1B SNPs
had individual and combined effects on fasting glucose in the
Chinese populations. The effect sizes of the risk alleles were similar
to what they were reported in other ethnics [18]. However, we
failed to find any effect of GCKR on fasting glucose although this
association had been replicated in different samples [9,10,18,19].
One possible explanation for the negative finding in our samples is
Table 2. Association between GCK, GCKR, G6PC2 and MTNR1B variants and traits related to glucose metabolism.
n GCK rs1799884 GCKR rs780094 G6PC2 rs16856187 MTNR1B rs10830963
Effect allele/other allele A/G A/G C/A G/C
Fasting glucose (mmol/l) 3,239,3,277 Beta(SE) 0.0591(0.0149) 0.0071(0.0123) 0.0481(0.0133) 0.0695(0.0124)
P 7.2610
25 0.5657 0.0003 2.0610
28
2h glucose (mmol/l) 3,237,3,275 Beta(SE) 0.0857(0.0327) 0.0487(0.0272) 0.0713(0.0293) 0.0365(0.0278)
P 0.0089 0.0729 0.0153 0.5705
Fasting insulin (pmol/l) 2,334,2,367 Beta(SE) 20.0091(0.0088) 20.0099(0.0071) 0.0040(0.0078) 0.0053(0.0072)
P 0.3048 0.1645 0.6055 0.4608
2h insulin (pmol/l) 2,338,2,369 Beta(SE) 0.0106(0.0134) 20.0057(0.0108) 0.0037(0.0117) 0.0092(0.0109)
P 0.4257 0.5976 0.7500 0.3989
HOMA-insulin resistance 2,334,2,367 Beta(SE) 20.0055(0.0092) 20.0104(0.0074) 0.0080(0.0081) 0.0115(0.0074)
P 0.5480 0.1597 0.3209 0.1232
HOMA-b 2,329,2,362 Beta(SE) 20.0211(0.0102) 20.0091(0.0083) 20.0127(0.0090) 20.0169(0.0083)
P 0.0396 0.2751 0.1586 0.0426
Insulinogenic index 954,960 Beta(SE) 20.0633(0.0254) 0.0057(0.0206) 20.0081(0.0223) 20.0492(0.0204)
P 0.0129 0.7807 0.7152 0.0162
First-phase insulin secretion 2,318,2,349 Beta(SE) 20.0325(0.0109) 20.0100(0.0089) 20.0245(0.0096) 20.0228(0.0089)
P 0.0030 0.2602 0.0108 0.0102
Second-phase insulin secretion 2,318,2,349 Beta(SE) 20.0215(0.0094) 20.0080(0.0076) 20.0093(0.0083) 0.0001(0.0076)
P 0.0223 0.2915 0.2624
a 0.9933
Triglyceride (mmol/l) 3,229,3,267 Beta(SE) 20.0003(0.0313) 0.0946(0.0257) 0.0703(0.0279) 0.0089(0.0262)
P 0.9927 0.0002 0.0118 0.7323
p values,0.05 were shown in bold.
p values were adjusted for age and gender for first- and second- phases insulin secretion; and adjusted for age, gender and BMI for the other traits.
ap=0.0431 in a dominant genetic model.
doi:10.1371/journal.pone.0011761.t002
Table 3. Association between GCK, GCKR, G6PC2 and MTNR1B variants and type 2 diabetes in the Chinese population.
Chromosome Gene SNP
Common/rare
alleles
Risk allele for high
fasting glucose Rare allele frequency OR(95% CI) p value
Cases Controls
7 GCK rs1799884 G,A A 0.226 0.222 1.021(0.940–1.110) 0. 6227
2 GCKR rs780094 A,G G 0.491 0.455 1.156(1.078–1.240) 5.3610
25
2 G6PC2 rs16856187 A,C C 0.281 0.306 0.888(0.823–0.958) 0.0021
11 MTNR1B rs10830963 C,G G 0.429 0.425 1.018(0.949–1.092) 0.6155
The ORs with 95% CIs are shown for the risk allele for high fasting glucose.
doi:10.1371/journal.pone.0011761.t003
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relatively smaller than the other three SNPs (0.06–0.07mmol/l per
allele) [8]. Thus the statistical power of our samples (,60%) may
not be enough. Two previous studies reported an interaction effect
between GCKR rs780094 and GCK rs1799884 on fasting glucose,
which was not observed in our samples either. But considering the
variant showed opposite interaction effect in those two studies
[9,10], whether there was an interaction between SNPs from GCK
and GCKR still remained to be investigated in additional studies
with larger samples.
GCK and G6PC2 are enzymes related to glucose phosphory-
lation, which is the committed step of glucose metabolism.
MTNR1B is the receptor of melatonin which inhibits insulin
secretion through its effect on the formation of cGMP [20,21,22].
Figure 1. Combined effect of risk alleles for high fasting glucose from GCK rs1799884, G6PC2 rs16856187 and MTNR1B rs10830963
on quantitative traits. (a) fasting glucose (n=3,212); (b) 2 h glucose (n=3,212); (c) HOMA-b (n=2,304); (d) insulinogenic index (n=953); (e) first-
phase insulin secretion (n=2,294); (f) second-phase (n=2,294) insulin secretion. Data shown are mean6SE. Individuals carrying more risk alleles for
high fasting glucose tended to have higher glucose levels at both fasting (p=1.7610
213) and 2 h during OGTT (p=0.0009), lower HOMA-b
(p=0.0011), insulinogenic index (p=0.0017), first- (p=1.1610
27) and second-phases (p=0.0321) of insulin secretion.
doi:10.1371/journal.pone.0011761.g001
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fasting glucose levels [23,24,25]. There is no doubt that GCK,
G6PC2 and MTNR1B variants impaired beta cell function, which
was shown by current study as well as previous reports [6,9,26,27].
However, our data additionally suggested heterogeneity may exist
for how these genes impaired beta cell function. We found GCK
and G6PC2 variants affected both first- and second-phases insulin
secretion, but MTNR1B variants only showed an association to
first-phase insulin secretion in the same samples. MTNR1B
participates in insulin secretion through its inhibitory effect on
cGMP formation when activated by melatonin [21]. But the
underlying mechanism how MTNR1B regulated first- and/or
second- phases of insulin secretion is still elusive.
Among the four genes studied, we found only GCKR rs780094
and G6PC2 rs16856187 affected type 2 diabetes risk in our
samples. Although GCKR was also associated to triglyceride levels,
its association to type 2 diabetes was independent of triglyceride
(p=0.0001 after adjusting age, gender, BMI and triglyceride levels
as the confounding factors). MTNR1B rs10830963 was previously
reported to be associated with type 2 diabetes susceptibility in the
Chinese [11], but we failed to replicate this association even we
had sufficient statistical power (over 95%) to detect the reported
effect. A previous study [27] also reported these loci showed a
combined effect on type 2 diabetes susceptibility and led to a
younger age at diagnosis. However, neither the combined effect on
type 2 diabetes susceptibility nor the association with younger age
at diagnosis was replicated in our study (data not shown). It is
interesting that type 2 diabetes genes (e.g., KCNQ1 and SLC30A8)
showed limited impacts on fasting glucose in the normoglycemic
populations, although they also impaired insulin secretion [28,29].
How these genes regulate glucose metabolism and type 2 diabetes
susceptibility remained to be elucidated by functional studies.
Although we carried out this replication study in large samples
and indicated GCK, G6PC2 and MTNR1B had different effects on
first- and second-phases of insulin secretion, there are limitations
in our study. First, the two phases of insulin secretion were derived
from fasting and 120 min glucose and insulin levels, the estimation
would be more accurate if OGTT 30 and 60 min blood samples
were available. However, participants with 30 min blood samples
were limited in our study. Second, we didn’t adjust lifestyle (e.g.,
alcohol consumption and smoking) as confounding factors.
Whether there is interaction between lifestyle and these genetic
variants on glucose metabolism still remained unknown.
In conclusion, we showed that GCK, G6PC2 and MTNR1B
variants modulated fasting glucose levels while G6PC2 and GCKR
variants were associated with type 2 diabetes in the Shanghai
Chinese. Moreover, we found GCK and G6PC2 genetic variants
were associated to both first- and second-phases insulin secretion
while MTNR1B genetic variant was associated to first-phase insulin
secretion, but not second-phase insulin secretion.
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